IIM
KROS icon

INTECH Investment Management’s Keros Therapeutics KROS Stock Holding History

INTECH Investment Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,265
Closed -$270K – 2241
2025
Q4 		$270K Sell
13,265
-3,408
-20% -$59.8K ﹤0.01% 1811
2025
Q3 		$264K Sell
16,673
-2,426
-13% -$35.8K ﹤0.01% 1905
2025
Q2 		$255K Sell
19,099
-2,023
-10% -$27.3K ﹤0.01% 1967
2025
Q1 		$215K Buy
21,122
+2,241
+12% +$26K ﹤0.01% 2052
2024
Q4 		$299K Buy
18,881
+8,489
+82% +$441K ﹤0.01% 1833
2024
Q3 		$603K Buy
+10,392
New +$513K 0.01% 1128

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

INTECH Investment Management's KROS Position: Q1 2026 in Review

INTECH Investment Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 13,265 shares — an estimated $270K sold.

INTECH Investment Management first reported a position in KROS in Q3 2024 and held it in 6 quarters. The position peaked at $603K in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • INTECH Investment Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • INTECH Investment Management sold 13,265 Keros Therapeutics shares in Q1 2026, an estimated $270K.
  • INTECH Investment Management first reported a position in Keros Therapeutics in Q3 2024 and held it in 6 quarters.
  • INTECH Investment Management's Keros Therapeutics position peaked at $603K in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.